We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Products and Services for Diversifying Preclinical Models

An organoid.
Credit: AMSBIO.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

Until 1993, most clinical trial participants were men of European descent, leading to a lack of data on the safety and efficacy of treatments for women and diverse populations. Although attitudes in clinical trials are changing, inclusivity in preclinical research is still often overlooked, leading to critical gaps in our understanding of how drugs and treatments affect different populations even before they proceed to human trials.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

In a recent blog, to celebrate International Women's Day, AMSBIO discusses the use of a proposed intestinal organoid biobank to combat accessibility issues as well as raising the issues of the lack of reporting by gender in COVID-19 vaccine development, where women had a disproportionate number of side-effects, under-reported due to aggregated data.

AMSBIO is a global provider of human and animal biospecimens to help increase diversity in research. The company’s extensive biorepository houses an array of tissues from reliable sources, including a comprehensive selection of healthy tissues as well as a variety of disease states from different genders and ethnicities. For specific research needs, AMSBIO additionally offers a custom tissue procurement service to supply the samples to match your research demands, however complex the donor demographics required.

In addition, leveraging a powerful combination of novel organoids with proprietary lab-on-a-chip technology from partners ScreenIn3D (S3D) – AMSBIO is uniquely placed to help preclinical researchers cost effectively develop high throughput data-rich assays.

Alex Sim, CEO of AMSBIO said “A significant driver for future clinical trials came from the US Federal Drug Administration in 2023. The new FDA 2.0 legislation adds a layer of stratification in research by creating more gender, race and other demographics requirements for clinical trials and research programs. Both AMSBIO and ScreenIn3D can help your research translate this for societal benefit and positioning of combination therapies”.